IX BIOPHARMA LTD.
Last Updated: 13 Apr 2026
iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focused on developing and commercializing innovative therapies for diseases of the central nervous system via novel, patent-protected sublingual formulations. Our product pipeline includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management, as well as Wafesil and Silcap for erectile dysfunction. Additionally, we have developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer. Our nutraceuticals division, Entity Health Limited, is dedicated to the development and commercialization of nutraceutical products.
Country of registration | Singapore |
Registration number | 200405621W |
Local SIC | |
Incorporation date | 8 May 2004 |
Company age | 22 years |
Official entity type | Public Company Limited By Shares |
No. of officers | 20 |
Contact
Address:
20 COLLYER QUAY, #11-07, 20 COLLYER QUAY, Singapore 049319
Phone number:
Access Key Decision Makers
This is the legal entity page of IX BIOPHARMA LTD.. To access company info, company size, news , key makers’ emails, visit the profile pages above.
Associated business (1)
- IX BIOPHARMAView MoreSingaporeiX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focused on developing and commercializing innovative therapies for diseases of the central nervous system via novel, patent-protected sublingual formulations. Our product pipeline includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management, as well as Wafesil and Silcap for erectile dysfunction. Additionally, we have developed Xativa, the world's first freeze-dried sublingual medicinal cannabis wafer. Our nutraceuticals division, Entity Health Limited, is dedicated to the development and commercialization of nutraceutical products.
This is the legal entity page of IX BIOPHARMA LTD.. To access company info, company size, news, key maker's emails, visit the profile pages above.
Financials
Fiscal/Budgeting Period | April - June |
Auditor | PRICEWATERHOUSECOOPERS LLP |
Revenue | 11m - 25m |
Financial period end date | 30 Jun 2022 |
Share Capital - Ordinary shares | SGD 95,411,168 |
Last updated: 13 Apr 2026
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Discover More Companies
Lookalike companies
* This profile contains information from ACRA Information on Corporate Entities from Accounting and Corporate Regulatory Authority which is made available under the terms of the Singapore Open Data Licence version 1.0. Information and datasets on our website are provided on an “as is” and “as available” basis. This website makes no representations or warranties concerning the datasets, including but not limited to any representation or warranty as to the accuracy, completeness, reliability, continued availability, timeliness, non-infringement, title, quality, or fitness for any particular purpose of the datasets to the fullest extent permitted by the law.
Frequently Asked Questions (FAQ)
- What is the address of IX BIOPHARMA LTD.?
- Where is IX BIOPHARMA LTD.'s headquarter?
- What is IX BIOPHARMA LTD.'s contact number?
- What IX BIOPHARMA LTD.'s spending power?
- Does IX BIOPHARMA LTD. have a presence in the domain it operates in?